Abstract
This chapter highlights single-chain triplebodies (sctbs), recombinant proteins derived from single-chain Fv antibody fragments (scFvs), which carry three scFvs arranged in tandem in a single polypeptide chain. Sctbs carrying binding sites for two copies of the same antigen on the tumor cell are called “triplebodies with bivalent, mono-specific targeting.” Sctbs addressing two different target antigens on the same tumor cell plus a trigger molecule are “dual-targeting” agents. Prototype 19-16-19 is discussed as example of mono-targeting agent, specific for CD19 on B-lymphoid leukemia cells and recruiting natural killer (NK) cells and macrophages as cytotoxic effectors via the trigger CD16. The sctb 123-16-33 is a prototypical example of “dual-targeting” agent specific for CD123 and CD33 on acute myeloid leukemia cells. The anticipated benefits of dual- over mono-specific targeting and of the triplebody format in general are outlined.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S, Noppeney R, Viardot A, Hess G, Schuler M, Einsele H, Brandl C, Wolf A, Kirchinger P, Klappers P, Schmidt M, Riethmuller G, Reinhardt C, Baeuerle PA, Kufer P (2008) Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 321(5891):974–977
Bruenke J, Barbin K, Kunert S, Lang P, Pfeiffer M, Stieglmaier K, Niethammer D, Stockmeyer B, Peipp M, Repp R, Valerius T, Fey GH (2005) Effective lysis of lymphoma cells with a stabilised bispecific single-chain Fv antibody against CD19 and FcgammaRIII (CD16). Br J Haematol 130(2):218–228
Chames P, Baty D (2009) Bispecific antibodies for cancer therapy: the light at the end of the tunnel? MAbs 1(6):539–547
Dick JE (2008) Stem cell concepts renew cancer research. Blood 112(13):4793–4807
Feuring-Buske M, Frankel AE, Alexander RL, Gerhard B, Hogge DE (2002) A diphtheria toxin-interleukin 3 fusion protein is cytotoxic to primitive acute myeloid leukemia progenitors but spares normal progenitors. Cancer Res 62(6):1730–1736
Fleit HB (1991) Monoclonal antibodies to human neutrophil Fc gamma RIII (CD16) identify polypeptide epitopes. Clin Immunol Immunopathol 59(2):222–235
Frankel A, Liu JS, Rizzieri D, Hogge D (2008) Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia. Leuk Lymphoma 49(3):543–553
Guettinger Y, Barbin K, Peipp M, Bruenke J, Dechant M, Horner H, Thierschmidt D, Valerius T, Repp R, Fey GH, Stockmeyer B (2010) A recombinant bispecific single-chain fragment variable specific for HLA class II and Fc alpha RI (CD89) recruits polymorphonuclear neutrophils for efficient lysis of malignant B lymphoid cells. J Immunol 184(3):1210–1217
Handgretinger R, Zugmaier G, Henze G, Kreyenberg H, Lang P, von Stackelberg A (2010) Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemia. Leukemia 25:181–184
Hartmann F, Renner C, Jung W, Deisting C, Juwana M, Eichentopf B, Kloft M, Pfreundschuh M (1997) Treatment of refractory Hodgkin’s disease with an anti-CD16/CD30 bispecific antibody. Blood 89(6):2042–2047
Hosen N, Park CY, Tatsumi N, Oji Y, Sugiyama H, Gramatzki M, Krensky AM, Weissman IL (2007) CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia. Proc Natl Acad Sci USA 104(26):11008–11013
Jin L, Lee EM, Ramshaw HS, Busfield SJ, Peoppl AG, Wilkinson L, Guthridge MA, Thomas D, Barry EF, Boyd A, Gearing DP, Vairo G, Lopez AF, Dick JE, Lock RB (2009) Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell 5(1):31–42
Jordan CT, Upchurch D, Szilvassy SJ, Guzman ML, Howard DS, Pettigrew AL, Meyerrose T, Rossi R, Grimes B, Rizzieri DA, Luger SM, Phillips GL (2000) The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia 14(10):1777–1784
Kellner C, Bruenke J, Stieglmaier J, Schwemmlein M, Schwenkert M, Singer H, Mentz K, Peipp M, Lang P, Oduncu F, Stockmeyer B, Fey GH (2008) A novel CD19-directed recombinant bispecific antibody derivative with enhanced immune effector functions for human leukemic cells. J Immunother 31(9):871–884
Kugler M, Stein C, Kellner C, Mentz K, Saul D, Schwenkert M, Schubert I, Singer H, Oduncu F, Stockmeyer B, Mackensen A, Fey GH (2010) A recombinant trispecific single-chain Fv derivative directed against CD123 and CD33 mediates effective elimination of acute myeloid leukaemia cells by dual targeting. Br J Haematol 150(5):574–586
le Viseur C, Hotfilder M, Bomken S, Wilson K, Rottgers S, Schrauder A, Rosemann A, Irving J, Stam RW, Shultz LD, Harbott J, Jurgens H, Schrappe M, Pieters R, Vormoor J (2008) In childhood acute lymphoblastic leukemia, blasts at different stages of immunophenotypic maturation have stem cell properties. Cancer Cell 14(1):47–58
Lillemeier BF, Mortelmaier MA, Forstner MB, Huppa JB, Groves JT, Davis MM (2010) TCR and Lat are expressed on separate protein islands on T cell membranes and concatenate during activation. Nat Immunol 11(1):90–96
Marschalek R, Greil J, Lochner K, Nilson I, Siegler G, Zweckbronner I, Beck JD, Fey GH (1995) Molecular analysis of the chromosomal breakpoint and fusion transcripts in the acute lymphoblastic SEM cell line with chromosomal translocation t(4;11). Br J Haematol 90(2):308–320
Muller D, Kontermann RE (2007) Recombinant bispecific antibodies for cellular cancer immunotherapy. Curr Opin Mol Ther 9(4):319–326
Nimmerjahn F, Ravetch JV (2005) Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science 310(5753):1510–1512
Nimmerjahn F, Ravetch JV (2006) Fcgamma receptors: old friends and new family members. Immunity 24(1):19–28
Roberts AW, He S, Bradstock KF, Hertzberg MS, Durrant STS, Ritchie D, Lewis ID, Marlton P, McLachlan AJ, Yeadon TM, Busfield SJ, Barnden MJ, Davis R, Hosback S, Mirosa D, Biondo M, Bamford S, DeWitte M, Basser R (2008) A phase 1 and correlative biological study of CSL360 (anti-CD123 mAb) in AML. ASH annual meeting abstracts, 112, pp 2956–2964
Schubert I, Kellner C, Stein C, Kugler M, Schwenkert M, Saul D, Mentz K, Singer H, Stockmeyer B, Hillen W, Mackensen A, Fey GH (2011) A single-chain triplebody with specificity for CD19 and CD33 mediates effective lysis of mixed lineage leukemia cells by dual targeting. MAbs 3(1):21–30
Sievers EL, Appelbaum FR, Spielberger RT, Forman SJ, Flowers D, Smith FO, Shannon-Dorcy K, Berger MS, Bernstein ID (1999) Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood 93(11):3678–3684
Silla LM, Chen J, Zhong RK, Whiteside TL, Ball ED (1995) Potentiation of lysis of leukaemia cells by a bispecific antibody to CD33 and CD16 (Fc gamma RIII) expressed by human natural killer (NK) cells. Br J Haematol 89(4):712–718
Singer H, Kellner C, Lanig H, Aigner M, Stockmeyer B, Oduncu F, Schwemmlein M, Stein C, Mentz K, Mackensen A, Fey GH (2010) Effective elimination of acute myeloid leukemic cells by recombinant bispecific antibody derivatives directed against CD33 and CD16. J Immunother 33(6):599–608
Sutlu T, Alici E (2009) Natural killer cell-based immunotherapy in cancer: current insights and future prospects. J Intern Med 266(2):154–181
Taussig DC, Pearce DJ, Simpson C, Rohatiner AZ, Lister TA, Kelly G, Luongo JL, Danet-Desnoyers GA, Bonnet D (2005) Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia. Blood 106(13):4086–4092
Topp MS, Goekbuget N, Kufer P, Zugmaier G, Klinger M, Degenhard E, Neumann S, Horst HA, Viardot A, Schmid M, Ottmann OG, Schmidt M, Reinhardt C, Baeuerle PA, Nagorsen D, Hoelzer D, Bargou R (2009) Blinatumomab (anti-CD19 bite) for targeted therapy of minimal residual disease (MRD) in patients with B precursor acute lymphoblastic leukemia (ALL): update of an ongoing phase II study. Hematologica 94:54–59
van Rhenen A, van Dongen GA, Kelder A, Rombouts EJ, Feller N, Moshaver B, Stigter-van Walsum M, Zweegman S, Ossenkoppele GJ, Jan Schuurhuis G (2007) The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells. Blood 110(7):2659–2666
Zwaan CM, Reinhardt D, Zimmerman M, Hasle H, Stary J, Stark B, Dworzak M, Creutzig U, Kaspers GJ (2010) Salvage treatment for children with refractory first or second relapse of acute myeloid leukaemia with gemtuzumab ozogamicin: results of a phase II study. Br J Haematol 148(5):768–776
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Stein, C., Schubert, I., Fey, G.H. (2011). Trivalent and Trispecific Antibody Derivatives for Cancer Therapy. In: Kontermann, R. (eds) Bispecific Antibodies. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-20910-9_4
Download citation
DOI: https://doi.org/10.1007/978-3-642-20910-9_4
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-20909-3
Online ISBN: 978-3-642-20910-9
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)